Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a key step in the development of a potential new therapy. The study, named ...

Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a registered direct offering and a concurrent private ...

MC2-R is the only melanocortin receptor that does not respond to MSH peptides (Table 1). Thus MC2-R displays considerably greater ligand specificity than other members of this family. The ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may ... identifier NCT06565611. About Melanocortin 4 Receptor Agonists Effect on Obesity ...